Inovio [NASDAQ: INO] Wins Approval to Conduct Phase 3 Trial of its COVID-19 Vaccine
Inovio Pharmaceuticals, Inc. [NASDAQ: INO] share has skyrocketed 2.16% during the pre-market trading session after the firm disclosed that it has won the approval to carry out a clinical study in that country as part of the Phase III segment of INOVIO’s global Phase 2/3 trial, INNOVATE, for its DNA vaccine candidate for COVID-19, INO-4800. […]
